English
English Español Português 日本

Webinar

Originally Aired: April 13th, 2022

"When do I refer out?"
Best management practices for Diabetic Retinopathy

Dr. Ferrucci

Presented By:
Dr. Steven Ferrucci, OD, FAAO
"The challenge is knowing when to refer the patient out — not too soon and certainly not too late. The key takeaway? Structural health assessed through imaging is only half of it. Functional diagnostics are vital."

About the Webinar

Who is going to progress? When?

One of the most pressing concerns in primary eye care is accurately predicting which diabetic retinopathy patient is going to progress. The challenge is knowing when to refer the patient out — not too soon and certainly not too late. The key takeaway? Structural health assessed through imaging is only half of it. Functional diagnostics are vital.

In this webinar, I’m going to present the latest diagnostic tools and strategies to provide the most accurate and predictive patient information. I’ll be focusing on the portable and non-invasive RETeval® Device. It combines functional retina cell stress testing with pupil light response. This powerful combination provides a superior risk assessment for which patients are going to require an ocular intervention, compared to the current Standard of Care.
Talk to us about superior DR progression risk assessment

About

Dr. Steven Ferrucci, OD, FAAO

Dr. Ferrucci, OD, FAAO is both Chief of Optometry as well as Residency Director at the Sepulveda VA Ambulatory Care Center and Nursing Home. He is also an Assistant Professor at the Southern California College of Optometry.
Dr. Ferrucci’s clinical focus includes therapeutic treatment of glaucoma, cataracts, diabetic retinopathy, and posterior segment disease. He also performs on-site fluorescein angiography, including injections and digital imaging.

 

Dr. Ferrucci has lectured extensively, with a special interest in Diabetes, Diabetic Eye Disease, and Fluorescein Angiography. He has also published several articles in optometric journals, including The New England Journal of Optometry, Optometry and Vision Science, and Optometry: Journal of The AOA. He is an active member of the American Optometric Association and the National VA Optometric Association, as well as a fellow in both the American Academy of Optometry and the Optometric Retinal Society. He is currently President of the San Fernando Valley Optometric Society, and a consultant for the Accreditation Council on Optometric Education.

Talk to us about superior DR progression risk assessment
Dr. Ferrucci
cropped-cropped-LKC_logo_RGB_color_no_tagline_mini_400px.png
© 2024 LKC Technologies, Inc.

California Proposition 65 information

Prop-65Warning: This product can expose you to chemicals including lead, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

Substance Tables:

The table below lists substances which may be contained within LKC’s RETeval and RETevet products. Substances listed as Type 1 are within permissible levels in one or more of LKC’s products. Substances listed as Type 2 are used in the production of some components used in LKC products and may be present at trace levels, but are typically destroyed during processing. 

RETeval and RETevet Devices

Substance CAS # Type Listed as causing:
Nickel 7440-02-0 1 Cancer
Acrylonitrile 107-13-1 2
Ethylbenzine 100-41-4 2
Crystaline Silica 14808-60-7 1
Lead 7439-92-1 1 Cancer Developmental Toxicity Male Reproductive Toxicity Female Reproductive Toxicity
Methylene Chloride 75-09-2 2 Cancer Female Reproductive Toxicity
Bisphenol A 80-05-7 2
N-Hexane  110-54-3 2 Male Reproductive Toxicity